SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001062993-20-001128
Filing Date
2020-02-24
Accepted
2020-02-24 09:30:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 SC 13D/A sched13da.htm SC 13D/A 28539
2 GRAPHIC sched13dax001.jpg GRAPHIC 2061
  Complete submission text file 0001062993-20-001128.txt   32931
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Subject) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90437 | Film No.: 20642273
SIC: 2834 Pharmaceutical Preparations

Mailing Address 19 PLACE VENDOME PARIS I0 75001
Business Address 19 PLACE VENDOME PARIS I0 75001 158625500
DNCA FINANCE (Filed by) CIK: 0001752759 (see all company filings)

IRS No.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
Type: SC 13D/A